Results 21 to 30 of about 143,566 (359)
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance [PDF]
, 2019 Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising target for direct tumor-killing ...
Boothman, David A. +10 more
core +1 more source
Myocarditis with Immune Checkpoint Blockade [PDF]
New England Journal of Medicine, 2017 In their discussion of fulminant myocarditis and complete heart block during immune checkpoint therapy, Johnson et al. do not discuss the possible role of circulating anticonductive tissue autoantibodies (ACTA) in the pathogenesis of the sudden heart block and myocarditis.1 Since it is not known which autoantigens (other than troponin I, which was ...
Javid J, Moslehi +2 more
openaire +5 more sources
New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. [PDF]
, 2018 Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections, excessive alcohol consumption, or non ...
Karin, Michael
core +1 more source
Journal of Immunology Research, 2018 Tumor is the most serious threat to human beings. Although war against cancer has been launched over forty years, cancer treatment is still far away from being satisfactory.
Huan Zhao +3 more
doaj +1 more source
Biomedicines, 2022 Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that only
Sophie Rovers +6 more
doaj +1 more source
Checkpoint blockade in lymphoma [PDF]
Hematology, 2015 AbstractImmune checkpoint blockade therapy (CBT) was born of the combination of several elements: the understanding of some of the important immune regulation pathways in humans; the recognition that tumors can engage those pathways to evade immune responses; and the clinical development of monoclonal antibodies targeting checkpoint receptors to ...
openaire +2 more sources
Cancer immunotherapy using checkpoint blockade [PDF]
Science, 2018 The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte–associated protein 4 (CTLA-4) or the programmed cell death 1 (PD-1 ...
Antoni Ribas, Jedd D. Wolchok
openaire +4 more sources
Journal for ImmunoTherapy of Cancer, 2020 Background Programmed cell death protein 1 (PD-1) and CTLA4 combination blockade enhances clinical efficacy in melanoma compared with targeting either checkpoint alone; however, clinical response improvement is coupled with increased risk of developing ...
Peng Yang +13 more
doaj +1 more source
Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
Nanomaterials, 2021 Immune checkpoint receptor signaling pathways constitute a prominent class of “immune synapse,” a cell-to-cell connection that represses T-lymphocyte effector functions.
Chiara Cremolini +3 more
doaj +1 more source
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]
, 2016 BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas +11 more
core +2 more sources